Literature DB >> 16909026

Hypermetabolism in ALS: correlations with clinical and paraclinical parameters.

Jean-Claude Desport1, Frédéric Torny, Mathieu Lacoste, Pierre-Marie Preux, Philippe Couratier.   

Abstract

Despite a reduction in fat-free mass (FFM), a hypermetabolism has been reported with an average of 10% in amyotrophic lateral sclerosis (ALS) patients as compared with a healthy population. The objectives of this study were to confirm the level of hypermetabolism determined by using indirect calorimetry in 168 patients with a probable or a definite ALS and to study correlations with survival. Consecutive evaluations of resting energy expenditure (REE) were performed from diagnosis to the proximity of death in 44 ALS patients. Differences with the calculated value determined a DeltaREE. FFM was given by bioimpedance. At T(1), REE was significantly increased by an average of 14% as compared with the calculated value. 62.3% of ALS patients were considered as hypermetabolic. REE was correlated in univariate analysis with age, sex, clinical form at onset, presence of a denutrition, weight, FFM, phase angle and ALS Functional Rating Scale (ALSFRS). In multivariate analysis, REE was linked to age and FFM. DeltaREE was correlated in univariate analysis with sex, phase angle and manual muscle testing (MMT). In multivariate analysis, age and sex remained significantly correlated. During progression of ALS, REE levels remained higher than calculated values with a trend to decrease at proximity of death, whereas FFM remained stable. From T(1), survival was linked to MMT, ALSFRS, vital capacity, REE and phase angle. We confirmed the existence of a stable hypermetabolic state in ALS which depends mainly on age, sex and FFM. REE is a prognostic factor for survival in univariate analysis.

Entities:  

Mesh:

Year:  2005        PMID: 16909026     DOI: 10.1159/000089626

Source DB:  PubMed          Journal:  Neurodegener Dis        ISSN: 1660-2854            Impact factor:   2.977


  72 in total

1.  SOD1-G93A mice exhibit muscle-fiber-type-specific decreases in glucose uptake in the absence of whole-body changes in metabolism.

Authors:  Susan E Smittkamp; Jill K Morris; Gregory L Bomhoff; Mark E Chertoff; Paige C Geiger; John A Stanford
Journal:  Neurodegener Dis       Date:  2013-09-06       Impact factor: 2.977

2.  The in vivo contribution of motor neuron TrkB receptors to mutant SOD1 motor neuron disease.

Authors:  Jinbin Zhai; Weiguo Zhou; Jian Li; Christopher R Hayworth; Lei Zhang; Hidemi Misawa; Rudiger Klein; Steven S Scherer; Rita J Balice-Gordon; Robert Gordon Kalb
Journal:  Hum Mol Genet       Date:  2011-08-04       Impact factor: 6.150

3.  Prediagnostic body size and risk of amyotrophic lateral sclerosis death in 10 studies.

Authors:  Éilis J O'Reilly; Molin Wang; Hans-Olov Adami; Alvaro Alonso; Leslie Bernstein; Piet van den Brandt; Julie Buring; Sarah Daugherty; Dennis Deapen; D Michal Freedman; Dallas R English; Graham G Giles; Niclas Håkansson; Tobias Kurth; Catherine Schairer; Elisabete Weiderpass; Alicja Wolk; Stephanie A Smith-Warner
Journal:  Amyotroph Lateral Scler Frontotemporal Degener       Date:  2018-04-16       Impact factor: 4.092

4.  Body mass index delineates ALS from FTD: implications for metabolic health.

Authors:  R M Ahmed; E Mioshi; J Caga; M Shibata; M Zoing; L Bartley; O Piguet; J R Hodges; M C Kiernan
Journal:  J Neurol       Date:  2014-06-24       Impact factor: 4.849

Review 5.  Challenges in the Understanding and Treatment of Amyotrophic Lateral Sclerosis/Motor Neuron Disease.

Authors:  Jeffrey Rosenfeld; Michael J Strong
Journal:  Neurotherapeutics       Date:  2015-04       Impact factor: 7.620

6.  Reduced activity of AMP-activated protein kinase protects against genetic models of motor neuron disease.

Authors:  M A Lim; M A Selak; Z Xiang; D Krainc; R L Neve; B C Kraemer; J L Watts; R G Kalb
Journal:  J Neurosci       Date:  2012-01-18       Impact factor: 6.167

7.  Estimating daily energy expenditure in individuals with amyotrophic lateral sclerosis.

Authors:  Edward J Kasarskis; Marta S Mendiondo; Dwight E Matthews; Hiroshi Mitsumoto; Rup Tandan; Zachary Simmons; Mark B Bromberg; Richard J Kryscio
Journal:  Am J Clin Nutr       Date:  2014-02-12       Impact factor: 7.045

8.  Serum irisin is upregulated in patients affected by amyotrophic lateral sclerosis and correlates with functional and metabolic status.

Authors:  Christian Lunetta; Andrea Lizio; Lucio Tremolizzo; Massimiliano Ruscica; Chiara Macchi; Nilo Riva; Patrick Weydt; Ettore Corradi; Paolo Magni; Valeria Sansone
Journal:  J Neurol       Date:  2018-10-22       Impact factor: 4.849

9.  1H-NMR-based metabolomic profiling of CSF in early amyotrophic lateral sclerosis.

Authors:  Hélène Blasco; Philippe Corcia; Caroline Moreau; Ségolène Veau; Clémentine Fournier; Patrick Vourc'h; Patrick Emond; Paul Gordon; Pierre-François Pradat; Julien Praline; David Devos; Lydie Nadal-Desbarats; Christian R Andres
Journal:  PLoS One       Date:  2010-10-08       Impact factor: 3.240

10.  Muscle mitochondrial uncoupling dismantles neuromuscular junction and triggers distal degeneration of motor neurons.

Authors:  Luc Dupuis; Jose-Luis Gonzalez de Aguilar; Andoni Echaniz-Laguna; Judith Eschbach; Frédérique Rene; Hugues Oudart; Benoit Halter; Caroline Huze; Laurent Schaeffer; Frédéric Bouillaud; Jean-Philippe Loeffler
Journal:  PLoS One       Date:  2009-04-30       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.